LLY
Eli Lilly and Company
- Stock-based compensation, 2025
- $626M
- YoY, 2025
- −3.1%
- 5-year CAGR
- +15.2%
- 10-year CAGR
- +11.1%
Stock-based compensation
Stock-based compensation by fiscal year
| Period | Stock comp | YoY |
|---|---|---|
| 2025 | $626M | −3.1% |
| 2024 | $646M | +2.7% |
| 2023 | $629M | +69.5% |
| 2022 | $371M | +8.3% |
| 2021 | $343M | +11.3% |
| 2020 | $308M | −1.4% |
| 2019 | $312M | +11.8% |
| 2018 | $280M | −0.6% |
| 2017 | $281M | +10.2% |
| 2016 | $255M | +17.2% |
| 2015 | $218M | +39.6% |
| 2014 | $156M | +7.7% |
| 2013 | $145M | +2.4% |
| 2012 | $142M | −4.0% |
| 2011 | $147M | −36.2% |
| 2010 | $231M | −37.3% |
| 2009 | $369M | — |
| 2008 | −$255M | — |
| 2007 | −$282M | — |